Schizophrenia Research
September 1, 2024
Ana Teresa Caliman-Fontes, Flávia Vieira, Gustavo C. Leal et al.
7 citations
Catatonia, documented since the 19th century, remains a significant challenge in terms of recognition and treatment. Over the last two decades, ketamine has brought new perspectives to psychiatry, sparking widespread interest. Concurrently, catatonia has attracted heightened scientific attention. Preliminary evidence suggests the therapeutic potential of ketamine for catatonia. We...
Research, Society and Development
July 15, 2024
G. Beanes, Beatriz A Carneiro, G. Marques et al.
Background: Low doses of different ketamine enantiomers have demonstrated rapid behavioural and biological actions in animals with depressive-like behavior. However, some authors report different effects depending on model of depression and ketamine isomer used. Objective: Our primary aim was to evaluate the effect of ketamine enantiomers on depressive-like behavior, anhedonic-like behavior and...
Journal of Psychiatric Research
August 1, 2023
Igor D. Bandeira, Gustavo C. Leal, Fernanda S. Correia-Melo et al.
There are significantly fewer options for the treatment of bipolar depression than major depressive disorder, with an urgent need for alternative therapies. In this pilot study, we treated six subjects with bipolar disorder types I and II (according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria) who had been in a current depressive episode for at...
Journal of Affective Disorders
June 1, 2023
Gustavo C. Leal, Breno Souza-Marques, Rodrigo P Mello et al.
Racemic ketamine is a mixture of (R)-ketamine (arketamine) and (S)-ketamine (esketamine), with the latter regarded as the main isomer for antidepressant effects. However, preclinical data and one open-label human trial suggest arketamine might exert a more potent and longer-lasting antidepressant effect with fewer side effects. We aimed to explore the feasibility of a randomized controlled...